Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
QuantumPharm, Inc. ( (HK:2228) ) just unveiled an announcement.
XtalPi Holdings has issued a positive profit alert, signaling a turnaround from a net loss of about RMB1.5 billion in 2024 to an expected net profit of at least RMB100 million in 2025, marking its first full-year profit. The shift is driven by a projected revenue surge to no less than RMB780 million, substantially narrowing losses in its core intelligent robotics and drug discovery operations.
Additional contributions to the profit reversal include a sharp rise in fair value gains on financial assets measured at fair value through profit or loss, expected to exceed RMB500 million, and the removal of large non-cash fair value losses tied to convertible redeemable preferred shares converted upon listing. The company cautioned that the figures are based on unaudited management accounts and may be subject to change, urging investors to act carefully until full annual results for 2025 are released.
The most recent analyst rating on (HK:2228) stock is a Hold with a HK$12.50 price target. To see the full list of analyst forecasts on QuantumPharm, Inc. stock, see the HK:2228 Stock Forecast page.
More about QuantumPharm, Inc.
XtalPi Holdings Limited is a Cayman Islands-incorporated technology company listed in Hong Kong that operates through a group focused on intelligent robotics solutions and drug discovery solutions. The business leverages advanced technologies to support pharmaceutical research and automation, positioning itself within the broader life sciences and high-tech innovation sectors.
Average Trading Volume: 70,349,109
Technical Sentiment Signal: Buy
Current Market Cap: HK$41.89B
See more insights into 2228 stock on TipRanks’ Stock Analysis page.